Biotech Values

[dewophile]

I listened thanks
One of the reasons they think it was the LNP was because they saw dose dependent liver effects preclinically (presumably at doses higher than what they thought they would need in humans).
It would have been nice if Brad Loncar simply asked him if they saw the same liver effects preclinically in the next generation system. Seems like an obvious follow up question to have asked
The company did mention their confidence in the second generation LNP because it has been tested by others in about 75 patients, but he also mentioned they also modified it with a proprietary GALNAc liver targeting moiety. It would have been nice to know if the outlicensed LNP had this modification or was an LNP without the GALNAC attached